Director/PDMR Shareholding

RNS Number : 7844N

GlaxoSmithKline PLC

24 February 2009

 



Notification of Transactions of Directors and

Persons Discharging Managerial Responsibility

Vesting of awards made under GlaxoSmithKline's share plans in 2006

This notification, prepared in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), sets out the vesting of share options made in 2006, under the GlaxoSmithKline Share Option Plan.

The three-year performance period for the GlaxoSmithKline Share Option Plan awards made to appointed CET members in 2006, at an option price of £14.68 (or US$51.02 in the case of ADSs), which commenced on 1 January 2006, came to an end on 31 December 2008. The performance conditions for this grant were not fully met for awards made to the then Executive Directors and CET members who are all persons discharging managerial responsibility. The Remuneration Committee of the Board of GlaxoSmithKline therefore confirmed that 50.7% of the original grant was exercisable.

	Number of options over Shares/ADSs exercisable
	Shares	ADSs
Mr A P Witty*	89,993
Mr J S Heslop*	117,117
Mr J M Clarke	89,993
Mr M Dunoyer	35,490
Mr D J Phelan		44,997
Mr D Pulman		29,153

* denotes an Executive Director

Grants made in 2006, to senior executives who have since been appointed Executive Directors or CET members were not subject to performance conditions. The Remuneration Committee therefore confirmed that the whole of the original grant was exercisable.

	Number of options over Shares/ADSs exercisable
	Shares	ADSs
Dr M Slaoui*	68,520
Mr S M Bicknell	12,650
Mr E J Gray	26,800
Mr D Learmouth	12,650
Mr D S Redfern	26,800
Ms C Thomas	20,180
Mr J R Stephenne	68,520
Mr W C Louv		11,870

*denotes an Executive Director

The Company, Directors, and Persons Discharging Managerial Responsibility were advised of these transactions on 23 February 2009.

V A Whyte

Deputy Company Secretary

24 February 2009

Enquiries:
UK Media enquiries:	Philip Thomson	[phone]
	David Outhwaite	[phone]
	Stephen Rea	[phone]
US Media enquiries:	Nancy Pekarek	[phone]
	Mary Anne Rhyne	[phone]
	Kevin Colgan	[phone]
	Sarah Alspach	[phone]
European Analyst/Investor enquiries:	David Mawdsley	[phone]
	Sally Ferguson	[phone]
	Gary Davies	[phone]
US Analyst/ Investor enquiries:	Tom Curry	[phone]
	Jen Hill	[phone]

 

END

 

 

RDSFZLFLKLBBBBK